证券代码：300846 证券简称：首都在线 公告编号：2025-062 北京首都在线科技股份有限公司 关于为全资子公司提供担保的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 特别风险提示： 北京首都在线科技股份有限公司（以下简称"公司"）为全资子公司甘肃首 云智算科技有限公司（以下简称"甘肃首云"）、广州首云智算网络信息科技有 限公司（以下简称"广州首云"）、北京中瑞云祥信息科技发展有限公司（以下 简称"中瑞云祥"）、首都在线网络科技（上海）有限公司（以下简称"上海网 络"）向银行申请授信额度提供担保。同时，为支持子公司业务开展，公司为甘 肃首云提供不可撤销的连带责任担保，用于甘肃首云向政府申请享受算力券政策。 根据《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监 管指引第 2 号——创业板上市公司规范运作》《北京首都在线科技股份有限公司 章程》（以下简称"《公司章程》"）等相关规定，本事项需提交公司股东大会 审议，需经出席股东大会的股东（包括股东代理人）所持表决权的 2/3 以上通过。 公司及其子公司不存在对合并报表外单位提供担保的情况 ...

证券代码：300846 证券简称：首都在线 公告编号：2025-063 北京首都在线科技股份有限公司 关于变更注册资本并修订《公司章程》及制定、修订部分公司管 理制度的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 北京首都在线科技股份有限公司（以下简称"公司"）于 2025 年 6 月 10 日召开第 六届董事会第六次会议、第六届监事会第六次会议，审议通过了《关于变更注册资本并 修订<公司章程>部分条款的议案》《关于制定、修订部分公司管理制度的议案》《关于 制定、修订部分公司管理制度的议案》包括以下子议案：1、关于修订《北京首都在线科 技股份有限公司股东会议事规则》的议案；2、关于修订《北京首都在线科技股份有限公 司董事会议事规则》的议案；3、关于修订《北京首都在线科技股份有限公司董事会薪酬 与考核委员会议事规则》的议案；4、关于修订《北京首都在线科技股份有限公司董事会 提名委员会议事规则》的议案；5、关于修订《北京首都在线科技股份有限公司董事会审 计委员会议事规则》的议案；6、关于修订《北京首都在线科技股份有限公司董事会战略 委员会议事规则》的议案；7、 ...

证券代码：300846 证券简称：首都在线 公告编号：2025-064 北京首都在线科技股份有限公司 关于召开 2025 年第二次临时股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 北京首都在线科技股份有限公司（以下简称"公司"）第六届董事会第六次会议审 议通过了《关于提请召开2025年第二次临时股东大会的议案》，定于2025年6月26日（周 四）召开公司2025年第二次临时股东大会。现将本次股东大会具体召开事宜通知如下： 2、会议召集人：公司董事会 3、会议召开的合法、合规性：本次会议的召开符合有关法律、行政法规、规范性文 件、深圳证券交易所的业务规则和《北京首都在线科技股份有限公司章程》（以下简称 "《公司章程》"）的规定。 4、会议召开时间： （1）现场会议时间：2025年6月26日（周四）下午14:30 （2）网络投票时间：2025年6月26日（周四） 其中，通过深圳证券交易所交易系统进行网络投票的具体时间为2025年6月26日 9:15—9:25，9:30-11:30和13:00-15:00；通过深圳证券交易所互联网投票系统投票的具体 ...

证券代码：300846 证券简称：首都在线 公告编号：2025-061 北京首都在线科技股份有限公司 第六届监事会第六次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 一、监事会会议召开和出席情况 1、北京首都在线科技股份有限公司（以下简称"公司"）于 2025 年 6 月 9 日以邮 件方式向全体监事发出第六届监事会第六次会议通知。 2、本次会议于 2025 年 6 月 10 日在公司会议室以现场与通讯相结合的方式召开。 3、本次会议由监事会主席孙捷女士主持，应出席监事 3 名，实际出席监事 3 名。 4、本次会议的召集、召开、议案审议程序符合《中华人民共和国公司法》（以下简 称"《公司法》"）《北京首都在线科技股份有限公司章程》（以下简称"《公司章程》"） 和《北京首都在线科技股份有限公司监事会议事规则》等有关规定，会议程序和结果合 法有效。 二、监事会会议审议情况 经与会监事审议，以投票表决的方式通过了以下议案： （一）审议通过了《关于为全资子公司提供担保的议案》 表决结果：3 票同意；0 票反对；0 票弃权。本议案获得通过。 本议案尚需提交公 ...

经与会董事审议，以投票表决的方式通过了以下议案： 证券代码：300846 证券简称：首都在线 公告编号：2025-060 北京首都在线科技股份有限公司 第六届董事会第六次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 一、会议召开情况 （一）审议通过了《关于为全资子公司提供担保的议案》 北京首都在线科技股份有限公司（以下简称"公司"）第六届董事会第六次会议于 2025 年 6 月 10 日在公司会议室以现场与通讯相结合的方式召开。会议通知于 2025 年 6 月9日以邮件方式送达各位董事，各位董事确认收悉。会议由公司董事长曲宁先生主持， 应出席董事 7 人，实际出席董事 7 人，公司全体监事和高级管理人员列席了会议。会议 的召开符合《中华人民共和国公司法》（以下简称"《公司法》"）《北京首都在线科 技股份有限公司章程》（以下简称"《公司章程》"）和《北京首都在线科技股份有限 公司董事会议事规则》的有关规定。 二、会议表决情况 为支持全资子公司的经营发展，公司董事会同意为子公司提供担保。前述事项有利 于促进其经营发展、提升其经营效率和盈利能力。 董事会 ...

Market Overview - The Shanghai Composite Index closed at 3393.26 points, above the six-month moving average, with a change of 0.23% [1] - The total trading volume of A-shares reached 838.618 billion yuan [1] Stocks Breaking Six-Month Moving Average - A total of 184 A-shares have surpassed the six-month moving average today [1] - Notable stocks with significant deviation rates include: - Qitian Technology: 11.69% deviation, closing price 14.38 yuan, with a daily increase of 20.03% and turnover rate of 15.50% [1] - Haochen Medical: 8.62% deviation, closing price 3.12 yuan, with a daily increase of 9.86% and turnover rate of 6.44% [1] - Jinyinhai: 7.58% deviation, closing price 21.00 yuan, with a daily increase of 9.66% and turnover rate of 6.43% [1] Additional Stocks with Deviation Rates - Other stocks with notable performance include: - Guangyun Technology: 7.45% deviation, closing price 14.13 yuan, with a daily increase of 9.20% and turnover rate of 4.78% [1] - Yaowang Technology: 5.93% deviation, closing price 7.12 yuan, with a daily increase of 7.88% and turnover rate of 13.64% [1] - Nuotai Biotech: 5.91% deviation, closing price 55.37 yuan, with a daily increase of 10.36% and turnover rate of 5.58% [1] Summary of Other Stocks - Additional stocks with lower deviation rates that have just crossed the six-month moving average include: - Guangdong Hongtu: just above the six-month line [1] - Xinhe Shares: just above the six-month line [1] - Songjing Shares: just above the six-month line [1]

Core Insights - The National Medical Products Administration approved 11 innovative drugs recently, with 10 coming from listed companies, indicating a significant advancement in China's pharmaceutical sector [1][4] - The approval of these drugs marks a pivotal moment for the industry, as it transitions into a phase of realizing the results of extensive research and development efforts [7][8] Group 1: Drug Approvals and Innovations - Among the approved drugs, several are the first of their kind in China, including Bai Jie Shen Zhou's injection of Zhenida Monoclonal Antibody, which is the first HER2 dual-target drug approved for cholangiocarcinoma [4][5] - Heng Rui Pharmaceutical's Apixaban is a multi-target tyrosine kinase inhibitor approved for use in advanced solid tumors, showcasing innovative treatment mechanisms [4][5] - The approval of Zai Jing Pharmaceutical's Jikaxitinib marks the first domestic JAK inhibitor for treating myelofibrosis, providing new options for patients with rare blood cancers [5][6] Group 2: Market Trends and Investment Opportunities - The innovative drug sector has seen a strong market performance, with 53 stocks hitting the daily limit up, indicating heightened investor interest [2][7] - Analysts predict that 2025 will be a transformative year for the pharmaceutical industry, characterized by increased revenue, profitability, and valuation improvements [1][7] - The Hong Kong innovation drug index has seen significant capital inflow, with over 200 million yuan in net inflow over the past 20 trading days, reflecting strong market sentiment [2][8] Group 3: Challenges and Future Outlook - Despite the positive developments, the innovative drug industry faces challenges such as high uncertainty in commercialization and intense competition among similar products [7][8] - The industry is supported by favorable policies and the growth of commercial health insurance, which enhances the payment environment for innovative drugs [8]

Core Insights - The rapid expansion of AI computing power in China is highlighted, with the current capacity reaching 3000P for training and 1000P for inference, and over 250 innovative solutions developed across various sectors [1] - The integration of computing power and network technology, referred to as "算网融合" (computing-network integration), is identified as a critical path for addressing the growing demand for AI computing resources and enhancing computational efficiency [3][6] - The Chinese intelligent computing power market is projected to grow significantly, with estimates indicating a market size of $25.9 billion by 2025, reflecting a 36.2% increase from 2024 [2] Industry Growth and Trends - The intelligent computing power scale in China is expected to reach 1037.3 EFLOPS by 2025, representing a 43% increase from 2024, and is projected to double by 2026 [2] - The compound annual growth rate (CAGR) for China's intelligent computing scale from 2023 to 2028 is forecasted at 46.2%, indicating a strong trend towards large and super-large intelligent computing centers [2] - The demand for AI models is driving a significant increase in computing power requirements, with current needs exceeding hardware supply by over 200 times [3] Technological Developments - Companies are focusing on transforming data centers into intelligent computing centers, emphasizing the need for efficient, green, and high-performance solutions [4][5] - Huawei is leveraging advanced technologies such as zero-loss networking and intelligent computing network scheduling to enhance computing resource utilization from 40% to 75% [5] - The integration of distributed computing architecture, low-latency networks, and virtualization technologies is essential for achieving high-quality development in computing power [6] Market Dynamics - The competition among enterprises for intelligent computing resources is intensifying, with a focus on optimizing computing infrastructure and enhancing service capabilities [5] - The shift from hardware-centric approaches to efficiency-driven models in AI computing is becoming evident, necessitating a demand-oriented and benefit-oriented approach in intelligent computing center construction [6]

Core Viewpoint - Beijing Capital Online Technology Co., Ltd. has reported that a portion of its fundraising special account has been frozen by the Chaoyang District People's Court in Beijing due to a contractual dispute with Tianxiang Ruiyi Technology Co., Ltd. [1][2] Group 1: Financial Impact - The amount frozen in the special account is 6,224,699.02 yuan, which represents 1.82% of the net proceeds from the company's A-share issuance in 2022 and a negligible impact on the company's recent audited net assets [2] - The company asserts that the frozen funds will not significantly affect the implementation of its fundraising investment projects or its normal operations and management [2] Group 2: Legal Context - As of the announcement date, the case related to the asset preservation is in the pre-litigation mediation stage, and the company has not received any formal legal documents from the court regarding the case [2] - The freezing of funds is a result of Tianxiang Ruiyi's lawsuit and request for property preservation due to payment disputes between the two companies [1][2] Group 3: Company Response - The company plans to assert its legal rights and take necessary measures to protect the interests of the company and its shareholders, aiming to lift the bank account freeze as soon as possible [2] - The company will continue to monitor the situation and fulfill its information disclosure obligations based on subsequent developments [2]

证券代码：300846 证券简称：首都在线 公告编号：2025-059 截至本公告披露日，公司尚未收到法院关于本次冻结公司银行账户的法律 文书、通知或其他信息。经公司初步自查了解，本次募集资金专项账户部分资 金被冻结系因公司与北京天翔睿翼科技有限公司（以下简称"天翔睿翼"）之 间的合同纠纷。公司与天翔睿翼互为供应商和客户关系，双方在合同履行过程 中就各自应收款项支付问题存在争议，未能协商一致，公司已就天翔睿翼欠款 另案申请仲裁，而此次资金冻结是由于天翔睿翼向法院提起诉讼并申请财产保 全所导致，最终冻结公司资金 6,224,699.02 元。 截至本公告披露日，上述涉及财产保全的案件处于诉前调解阶段，公司尚 1 户名 开户银行 银行账号 截至 2025 年 5 月 27 日账户余额 （元） 账户性质 本次被冻结 金额（元） 北京首都在 线科技股份 有限公司 中国民生银 行股份有限 公司北京陶 然桥支行 644397265 311,002,440.96 募集资金 专项账户 6,224,699.02 一、本次部分募集资金专项账户的部分资金被冻结基本情况 未收到法院送达的上述案件相关的其他正式法律文书。 三、本次部分 ...